文献速递妇科肿瘤

欧洲组织性宫颈癌筛查对宫颈癌死亡率影响的系统综述

Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review.
PubMed 文献 · Eur J Cancer · 2020-01-21

参会筛查女性较未参会者死亡率降低41%-92%,受邀女性较未受邀者降低17%-79%,但南欧和东欧缺乏数据,效应量在国家与研究间存在差异。

要点

  • 组织性筛查参会女性宫颈癌死亡风险较未参会者降低41%-92%。
  • 受邀女性较未受邀者死亡风险降低17%-79%,效应低于实际参会对比。
  • 南欧与东欧缺乏合格研究,证据主要来自西欧和北欧。

核心结论

  • 组织性宫颈癌筛查可降低已实施并监测筛查的欧洲地区的宫颈癌死亡率。
  • 效应量在国家与研究间存在差异,且南欧和东欧数据缺乏。

研究设计与样本

  • 系统综述,检索Embase、Medline和Web of Science等6个数据库至2018年3月。
  • 仅纳入随访至少5年的原始研究,采用经验证工具评估偏倚风险。

主要发现

  • 参会筛查女性较未参会者的宫颈癌死亡率降低范围为41%至92%(7项研究)。
  • 西欧降低45%-92%,北欧降低41%-87%,3项较新研究降低66%-92%。
  • 受邀女性较未受邀者的死亡率降低范围为17%至79%(5项研究)。
  • 未发现随机对照试验,且无来自南欧和东欧的合格研究。
  • 7项研究于20世纪开展,偏倚风险评估得分较低。

临床怎么用

  • 在已实施组织性筛查的地区,参会筛查与宫颈癌死亡率下降相关,支持持续开展并监测筛查项目。
  • 受邀对比的死亡率下降幅度低于参会对比,提示需关注筛查参与率对人群效果的影响。
  • 南欧和东欧缺乏本土证据,引用本综述结论时需注意地区外推性。

局限性

  • 仅纳入观察性研究,无随机对照试验证据。
  • 南欧和东欧无合格研究,地理覆盖不完整。
  • 7项研究为20世纪开展且偏倚风险评估得分较低。
  • 效应量在国家与研究间存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Organised cervical cancer (CC) screening programmes are delivered in many different ways across the European Union and its regions. Our aim was to systematically review the impact of these programs on CC mortality. METHODS: Two independent reviewers identified all eligible studies investigating the effect of organised screening on CC mortality in Europe. Six databases including Embase, Medline and Web of Science were searched (March 2018) with predefined inclusion and exclusion criteria. Only original studies with at least five years of follow-up were considered. Validated tools were used to assess the risk of bias of the included studies. RESULTS: Ten observational studies were included: seven cohort and three case-control studies. No randomised controlled trials were found, and there were no eligible studies from the eastern and southern part of Europe. Among the eligible studies, seven were conducted in the twentieth century; they scored lower on the risk of bias assessment. CC mortality reduction for women attending organised screening vs. non-attenders ranged from 41% to 92% in seven studies. Reductions were similar in Western (45-92%) and Northern (41-87%) Europe and were higher in the three more recent studies (66-92%). For invited vs. non-invited women, this reduction ranged from 17% to 79% in five studies. CONCLUSION: Although data were lacking in Southern and Eastern Europe and the effect size varied between countries and studies, this systematic review provides evidence that organised CC screening reduces CC mortality in those parts of Europe where CC screening was implemented and monitored.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jansen EEL, Zielonke N, Gini A, et al. Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review. Eur J Cancer. 2020. PMID: 31980322. doi:10.1016/j.ejca.2019.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。